This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

H.C. Wainwright Keeps Their Buy Rating on Corcept Therapeutics (CORT)

Tipranks - Tipranks - Tue Jun 2, 6:52AM CDT

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $95.00.

Claim 55% Off TipRanks

According to TipRanks, Ramakanth is a 5-star analyst with an average return of 16.3% and a 44.91% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Precigen, and Corcept Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Corcept Therapeutics with a $97.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Corcept Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $164.9 million and a GAAP net loss of $31.2 million. In comparison, last year the company earned a revenue of $157.21 million and had a net profit of $20.55 million

Based on the recent corporate insider activity of 137 insiders, corporate insider sentiment is neutral on the stock. Last month, Joseph Douglas Lyon, the Chief Accounting & Technology Officer of CORT sold 5,000.00 shares for a total of $325,000.00.

Read More on CORT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).